Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Taylor

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Rheumatology (Oxford, England)|February 27, 2019
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritisPeter C Taylor
Current Opinion in Pharmacology|February 23, 2010
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseasesPeter C Taylor
Clinical Medicine (London, England)|November 17, 2020
Update on the diagnosis and management of early rheumatoid arthritisPeter C Taylor
Expert Review of Clinical Immunology|May 19, 2010
Rituximab in the treatment of rheumatoid arthritisPeter C Taylor
Internal Medicine (Tokyo, Japan)|February 14, 2003
Anti-TNFalpha therapy for rheumatoid arthritis: an updatePeter C Taylor
Current Opinion in Pharmacology|June 18, 2003
Antibody therapy for rheumatoid arthritisPeter C Taylor
The Lancet. Rheumatology|January 22, 2024
Pain in the joints and beyond; the challenge of rheumatoid arthritisPeter C Taylor
Rheumatology (Oxford, England)|January 30, 2025
Towards better personalized care in rheumatoid arthritisPeter C Taylor
Nature Reviews. Rheumatology|October 12, 2023
Are TNF inhibitors still the agent of choice for RA?Peter C Taylor
Current Pharmaceutical Design|May 29, 2003
Anti-cytokines and cytokines in the treatment of rheumatoid arthritisPeter C Taylor
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Rheumatology (Oxford, England)|February 27, 2019
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritisPeter C Taylor
Current Opinion in Pharmacology|February 23, 2010
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseasesPeter C Taylor
Clinical Medicine (London, England)|November 17, 2020
Update on the diagnosis and management of early rheumatoid arthritisPeter C Taylor
Expert Review of Clinical Immunology|May 19, 2010
Rituximab in the treatment of rheumatoid arthritisPeter C Taylor
Internal Medicine (Tokyo, Japan)|February 14, 2003
Anti-TNFalpha therapy for rheumatoid arthritis: an updatePeter C Taylor
Current Opinion in Pharmacology|June 18, 2003
Antibody therapy for rheumatoid arthritisPeter C Taylor
The Lancet. Rheumatology|January 22, 2024
Pain in the joints and beyond; the challenge of rheumatoid arthritisPeter C Taylor
Rheumatology (Oxford, England)|January 30, 2025
Towards better personalized care in rheumatoid arthritisPeter C Taylor
Nature Reviews. Rheumatology|October 12, 2023
Are TNF inhibitors still the agent of choice for RA?Peter C Taylor
Current Pharmaceutical Design|May 29, 2003
Anti-cytokines and cytokines in the treatment of rheumatoid arthritisPeter C Taylor
Pageof 25